Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy
Conditions: HER2-positive Breast Cancer; Stage I Breast Cancer Intervention: Biological: Trastuzumab and pertuzumab Subcutaneous Fixed-Dose Combination Sponsors: Fundacio Clinic Barcelona; SOLTI Breast Cancer Research Group; Roche Pharma AG Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Addiction | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin | Neoadjuvant Therapy | Research